Editorial
Copyright ©2011 Baishideng Publishing Group Co.
World J Biol Chem. Oct 26, 2011; 2(10): 215-225
Published online Oct 26, 2011. doi: 10.4331/wjbc.v2.i10.215
Table 1 Decavanadate in vivo studies in 2001-2010
TissueEffectsAdministration modeExposition timeRef.
HAntioxidant enzymesip1, 7 d[7]
H/K/LHistological effectsip1, 7 d[8]
LVanadium accumulationiv12, 24 h, 7 d[9]
Antioxidant enzymes
H/BVanadium accumulationiv1, 6, 12 h[10]
HLipid peroxidationiv1, 6, 12 h[11]
Antioxidant enzymes
HVanadium accumulationiv1, 7 d[12]1
Antioxidant enzymes
Table 2 Decavanadate in vitro studies in 2001-2010
Protein/effectVanadate speciesYrRef.
DNA-binding proteinV102002[70]
Methemoglobin reductase inhibitionV102003[73]
Actomyosin ATPase inhibitionV102004[20]
Muscle contraction regulationV102004[21]
ATP sensitive cation -channelV102004[76]
TRPM4 cation channelsV102004[71]
G-Actin polymerization inhibitorV10, V42006[36]
RNA triphosphataseV102006[72]
P2X receptor antagonistV102006[74]
Insulin mimeticsV10 compounds2007[57]
Back-door binding to myosinV102007[22]
Porin (VDC) modulatorV102007[75]
Mitochondrial membrane depolarizationV10, V12007[54]
Mitochondrial oxygen consumptionV10, V12007[55]
Extracellular matrix mineralizationV10, V12008[77]
Cardiomyocytes necrotic cell deathV10, V12008[78]
Gelatine-mixturesV102008[79]
Adipocytes glucose accumulationV102009[68]
Actin oxidation and vanadyl formationV102009[52]
Anticancer activityV10 compounds2009[58]
ATPase activity in synaptic membranesV102009[80]
Membrane models interactionV102009[81]
DNA cleavageV102010[82]
Actin structure and functionV102010[2]
Anticancer activityV10 compounds2010[59]